Monopar Therapeutics Inc. (MNPR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Monopar Therapeutics Inc. on November 10, 2025, covering events occurring on November 9, 2025. The company, incorporated in Delaware and trading on the Nasdaq Capital Market, is a biopharmaceutical firm focused on liver disease treatments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific corporate event rather than a periodic financial statement.
Material Changes
There are no material financial changes reported in this document. The primary event is the announcement of new clinical data.
Guidance, Outlook, and Management Commentary
Under Item 7.01 (Regulation FD Disclosure), Monopar announced the presentation of new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study. This data was presented at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025. The full press release is included as Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific clinical outcomes of the ALXN1840-WD-204 study.
- Verify the impact of the new data on the company's development timeline for Wilson's disease treatment.
- Check subsequent filings for any updates to cash runway or financing needs following this data readout.